Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial
Julie Thompson, Natasha Jones, Ali Al-Khafaji, Shahid Malik, David Reich, Santiago Munoz, Ross MacNicholas, Tarek Hassanein, Lewis Teperman, Lance Stein, Andrés Duarte-Rojo, Raza Malik, Talal Adhami, Sumeet Asrani, Nikunj Shah, Paul Gaglio, Anupama Duddempudi, Brian Borg, Rajiv Jalan, Robert Brown, Heather Patton, Rohit Satoskar, Simona Rossi, Amay Parikh, Ahmed ElSharkawy, Parvez Mantry, Linda Sher, David Wolf, Marquis Hart, Charles Landis, Alan Wigg, Shahid Habib, Geoffrey McCaughan, Steven Colquhoun, Alyssa Henry, Patricia Bedard, Lee Landeen, Michael Millis, Robert Ashley, William Frank, Andrew Henry, Jan Stange, Ram Subramanian, VTI-208 Study Group, Julie Thompson, Natasha Jones, Ali Al-Khafaji, Shahid Malik, David Reich, Santiago Munoz, Ross MacNicholas, Tarek Hassanein, Lewis Teperman, Lance Stein, Andrés Duarte-Rojo, Raza Malik, Talal Adhami, Sumeet Asrani, Nikunj Shah, Paul Gaglio, Anupama Duddempudi, Brian Borg, Rajiv Jalan, Robert Brown, Heather Patton, Rohit Satoskar, Simona Rossi, Amay Parikh, Ahmed ElSharkawy, Parvez Mantry, Linda Sher, David Wolf, Marquis Hart, Charles Landis, Alan Wigg, Shahid Habib, Geoffrey McCaughan, Steven Colquhoun, Alyssa Henry, Patricia Bedard, Lee Landeen, Michael Millis, Robert Ashley, William Frank, Andrew Henry, Jan Stange, Ram Subramanian, VTI-208 Study Group
Abstract
Severe alcoholic hepatitis (sAH) is associated with a poor prognosis. There is no proven effective treatment for sAH, which is why early transplantation has been increasingly discussed. Hepatoblastoma-derived C3A cells express anti-inflammatory proteins and growth factors and were tested in an extracorporeal cellular therapy (ELAD) study to establish their effect on survival for subjects with sAH. Adults with sAH, bilirubin ≥8 mg/dL, Maddrey's discriminant function ≥ 32, and Model for End-Stage Liver Disease (MELD) score ≤ 35 were randomized to receive standard of care (SOC) only or 3-5 days of continuous ELAD treatment plus SOC. After a minimum follow-up of 91 days, overall survival (OS) was assessed by using a Kaplan-Meier survival analysis. A total of 203 subjects were enrolled (96 ELAD and 107 SOC) at 40 sites worldwide. Comparison of baseline characteristics showed no significant differences between groups and within subgroups. There was no significant difference in serious adverse events between the 2 groups. In an analysis of the intent-to-treat population, there was no difference in OS (51.0% versus 49.5%). The study failed its primary and secondary end point in a population with sAH and with a MELD ranging from 18 to 35 and no upper age limit. In the prespecified analysis of subjects with MELD < 28 (n = 120), ELAD was associated with a trend toward higher OS at 91 days (68.6% versus 53.6%; P = .08). Regression analysis identified high creatinine and international normalized ratio, but not bilirubin, as the MELD components predicting negative outcomes with ELAD. A new trial investigating a potential benefit of ELAD in younger subjects with sufficient renal function and less severe coagulopathy has been initiated. Liver Transplantation 24 380-393 2018 AASLD.
Trial registration: ClinicalTrials.gov NCT01471028.
© 2017 The Authors. Liver Transplantation published by Wiley Periodicals, Inc. on behalf of American Association for the Study of Liver Diseases.
Figures
References
- Crabb DW, Bataller R, Chalasani NP, Kamath PS, Lucey M, Mathurin P, et al.; for NIAAA Alcoholic Hepatitis Consortia . Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA alcoholic hepatitis consortia. Gastroenterology 2016;150:785‐790.
- Gao B, Bataller R. Alcoholic liver disease: Pathogenesis and new therapeutic targets. Gastroenterology 2011;141:1572‐1585.
- Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009;360:2758‐2769.
- Mehta G, Mookerjee RP, Sharma V, Jalan R. Systemic inflammation is associated with increased intrahepatic resistance and mortality in alcohol‐related acute‐on‐chronic liver failure. Liver Int 2015;35:724‐734.
- Thursz MR, Forrest EH, Ryder S; for STOPAH investigators . Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med 2015;373:282‐283.
- DiNubile MJ. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med 2015;373:281‐282.
- Verbeke L, Laleman W, Nevens F. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med 2015;373:281.
- Artru F, Louvet A, Mathurin P. Liver transplantation for patients with alcoholic hepatitis. Liver Int 2017;37:337‐339.
- Busuttil RW, DuBray BJ. Liver transplantation for alcoholic hepatitis. Ann Surg 2017;265:30‐31.
- Obed A, Stern S, Jarrad A, Lorf T. Six month abstinence rule for liver transplantation in sever alcoholic liver disease. World J Gastroenterol 2015;21:4423‐4426.
- Ezquer F, Bruna F, Calligaris S, Conget P, Ezquer M. Multipotent mesenchymal stromal cells: a promising strategy to manage alcoholic liver disease. World J Gastroenterol 2016;22:24‐36.
- Lanthier N, Lin‐Marq N, Rubbia‐Brandt L, Clément S, Goossens N, Spahr L. Autologouse bone marrow‐derived cell transplantation in decompensated alcoholic liver disease: what is the impact on liver histology and gene expression patterns? Stem Cell Res Ther 2017;8:88.
- Landeen LK, Van Allen J, Heredia N, Lapetoda J, Bedard PW, Brotherton JD, et al. Expression of acute‐phase proteins by ELAD C3A Cells. Transplantation 2015;99:208; 21st Annual International Congress of the International‐Liver‐Transplant‐Society (ILTS) July 08‐11, 2015, Chicago, IL.
- Bedard PW, Lapetoda J, Van Allen J, Heredia N, Michalopoulos GK, Landeen LK. ELAD VTL C3A cells may impact liver regeneration through secreted factors. Hepatology 2015;62(suppl 1):1071A.
- Teperman L. The ELAD Study Group . Bilirubin Improvement correlates with 90-day survival with use of the ELAD® system in a randomized, controlled study of subjects with acute alcoholic hepatitis or acute decompensation of cirrhosis [abstract]. Am J Transplant 2013;13(suppl 5):147.
- Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KV, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005;41:353‐358.
- Mitzner SR. Extracorporeal liver support‐albumin dialysis with the Molecular Adsorbent Recirculating System (MARS). Ann Hepatol 2011;10(suppl 1):S21‐S28.
- Larsen FS, Schmidt LE, Bernsmeier C, Rasmussen A, Isoniemi H, Patel VC, et al. High‐volume plasma exchange in patients with acute liver failure: an open randomised controlled trial. J Hepatol 2016;64:69‐78.
- Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007;45:1348‐1354.
- Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine‐‐reporting of subgroup analysis in clinical trials. N Engl J Med 2007;357:2189‐2194.
- O'Shea RS, Dasarathy S, McCullough AJ; for Practice Guideline Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology . Alcoholic liver disease. Hepatology 2010;51:307‐328.
Source: PubMed